GlassScriptPhysician profile
Nathan I Rothman
NPI 1285616136
$26,781.83
in general payments reported to CMS, 2019-2025
33 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,320 · 2020: $5,687 · 2021: $9,340 · 2022: $2,339 · 2023: $2,195 · 2024: $2,175 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,097.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16,168.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,682.36 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,321.18 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $979.04 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $746.52 | 2019-2025 | Xolair |
| Mylan Specialty L.P. | $726.40 | 2019-2024 | Yupelri |
| Amgen INC. | $684.59 | 2021-2024 | Tezspire |
| Genzyme Corporation | $533.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $474.69 | 2019-2022 | |
| Grifols USA, LLC | $324.00 | 2019-2024 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $293.16 | 2019-2021 | |
| Philips North America LLC | $244.20 | 2019-2024 | (Ak6) Vest Therapy |
| Inogen, INC. | $194.92 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Electromed, INC. | $187.46 | 2021-2024 | Smartvest |
| Verona Pharma, INC. | $177.30 | 2025 | Ohtuvayre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $158.11 | 2021-2022 | |
| Insmed, INC. | $133.29 | 2022-2025 | Arikayce, Brinsupri |
| Boston Scientific Corporation | $109.30 | 2019 | |
| Shionogi INC | $76.02 | 2022-2023 | Fetroja |
| Circassia INC. | $75.60 | 2019-2020 | |
| Pfizer INC. | $70.86 | 2024 | |
| Harmony Biosciences LLC | $59.12 | 2021-2022 | |
| Abbvie INC. | $51.75 | 2023 | Avycaz |
| Takeda Pharmaceuticals U.S.A., INC. | $48.80 | 2020-2025 | Glassia |
| Gilead Sciences, INC. | $39.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.98 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $35.54 | 2024 | Xarelto |
| Inari Medical, INC. | $31.33 | 2021 | |
| Viatris Specialty LLC | $29.81 | 2025 | Yupelri |
| Baxter Healthcare | $24.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.24 | 2021 | |
| Merck Sharp & Dohme LLC | $22.09 | 2025 | Capvaxive |
| Shire North American Group INC | $18.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.